DK97987A - Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation - Google Patents

Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation

Info

Publication number
DK97987A
DK97987A DK097987A DK97987A DK97987A DK 97987 A DK97987 A DK 97987A DK 097987 A DK097987 A DK 097987A DK 97987 A DK97987 A DK 97987A DK 97987 A DK97987 A DK 97987A
Authority
DK
Denmark
Prior art keywords
solubilization
proteins
pharmaceutical compositions
polymer conjugation
water
Prior art date
Application number
DK097987A
Other languages
English (en)
Other versions
DK97987D0 (da
DK169874B1 (da
Inventor
Nandini Katre
Michael James Knauf
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK97987A publication Critical patent/DK97987A/da
Publication of DK97987D0 publication Critical patent/DK97987D0/da
Application granted granted Critical
Publication of DK169874B1 publication Critical patent/DK169874B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK097987A 1985-06-26 1987-02-25 Farmaceutisk sammensætning indeholdende et vandopløseligt konjugat af protein og polymer og fremgangsmåde til fremstilling af dette konjugat DK169874B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74995585A 1985-06-26 1985-06-26
US74995585 1985-06-26
US8601252 1986-06-06
PCT/US1986/001252 WO1987000056A1 (en) 1985-06-26 1986-06-06 Solubilization of proteins for pharmaceutical compositions using polymer conjugation

Publications (3)

Publication Number Publication Date
DK97987A true DK97987A (da) 1987-02-25
DK97987D0 DK97987D0 (da) 1987-02-25
DK169874B1 DK169874B1 (da) 1995-03-20

Family

ID=25015921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK097987A DK169874B1 (da) 1985-06-26 1987-02-25 Farmaceutisk sammensætning indeholdende et vandopløseligt konjugat af protein og polymer og fremgangsmåde til fremstilling af dette konjugat

Country Status (17)

Country Link
EP (1) EP0229108B1 (da)
JP (1) JP2524586B2 (da)
KR (1) KR900004801B1 (da)
CA (1) CA1291708C (da)
DE (1) DE3676670D1 (da)
DK (1) DK169874B1 (da)
FI (1) FI93424C (da)
GR (1) GR861641B (da)
IE (1) IE59406B1 (da)
IL (1) IL79235A (da)
IN (1) IN163200B (da)
MX (1) MX174442B (da)
NZ (1) NZ216618A (da)
PH (1) PH25004A (da)
PT (1) PT82834B (da)
WO (1) WO1987000056A1 (da)
ZA (1) ZA864766B (da)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
ATE118686T1 (de) * 1989-08-07 1995-03-15 Debio Rech Pharma Sa Biologisch wirksame polymere arzneistoffderivate.
US5393735A (en) * 1990-08-09 1995-02-28 Rohm And Haas Company Herbicidal glutarimides
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
FR2658521B1 (fr) * 1990-02-19 1994-01-21 Serbioo Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
FR2658519B1 (fr) * 1990-02-19 1995-07-07 Serbio Substrats peptidiques pour identification du facteur xa.
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5312903A (en) * 1990-06-01 1994-05-17 E. I. Du Pont De Nemours And Company Lysine-glycosylated recombinant interleukin-2
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0642798T3 (da) * 1993-09-08 2007-09-10 Jolla Pharma Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ES2336857T3 (es) * 1995-05-04 2010-04-16 Gilead Sciences, Inc. Complejos de ligandos de acido nucleico.
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
EP0850064A1 (en) * 1995-09-14 1998-07-01 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DE69836222T2 (de) * 1997-01-15 2007-11-15 Phoenix Pharmacologics, Inc. Modifizierter tumor-nekrosefaktor
EP0973384A4 (en) 1997-02-13 2004-10-13 Sky High Llc ORGAN PRESERVATION SOLUTION
PT1075281E (pt) * 1998-04-28 2004-11-30 Applied Research Systems Conjugados poliol-ifn-beta
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN1264575C (zh) 1998-08-06 2006-07-19 山景药品公司 聚乙二醇或聚环氧乙烷－尿酸氧化酶结合物及其应用
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
CZ300762B6 (cs) 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
MXPA02001969A (es) * 1999-08-27 2003-07-21 Maxygen Aps Nuevas moleculas similares a interferon beta.
TR200101086A3 (da) * 1999-10-15 2001-08-21
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
NZ520261A (en) 2000-01-10 2003-10-31 Maxygen Holdings Ltd Granulocyte colony-stimulating factor PEG conjugates that exhibit an increased bioavailability and half-life in vivo and reduced side effects and immunogenicity
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CA2469846A1 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2003000278A1 (fr) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Onguents
CN1555268B (zh) 2001-07-17 2013-04-03 研究发展基金会 含促调亡蛋白质的治疗剂
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
HUE028163T2 (en) 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
CN101301475B (zh) 2002-06-21 2012-12-19 诺和诺德医疗保健公司 Peg化因子vii糖型
US7524931B2 (en) 2002-07-03 2009-04-28 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
NZ541124A (en) 2002-12-26 2008-08-29 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CA2534907C (en) * 2003-08-07 2014-04-29 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
PL1666496T3 (pl) 2003-08-25 2014-08-29 Toray Industries Kompozyt interferonu beta
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US7405198B2 (en) 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
US20080305518A1 (en) 2004-05-04 2008-12-11 Novo Nordisk Healthcare A/G O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
DK2586456T3 (da) 2004-10-29 2016-03-21 Ratiopharm Gmbh Omdannelse og glycopegylering af fibroblast vækstfaktor (FGF)
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
RU2304586C1 (ru) * 2006-03-27 2007-08-20 Михаил Николаевич Смирнов Препарат интерлейкина-2 и способ его получения
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP2010503630A (ja) * 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2008124406A2 (en) 2007-04-03 2008-10-16 Neose Technologies, Inc. Methods of treatment using glycopegylated g-csf
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
EP2197919B1 (en) 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
BRPI0905707B1 (pt) * 2008-01-18 2024-02-27 Dow Global Technologies Inc Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
MX356129B (es) 2008-01-22 2018-05-16 Araim Pharmaceuticals Inc Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
JP5592355B2 (ja) 2008-05-13 2014-09-17 アドヴァンスト リキッド ロジック インコーポレイテッド 液滴アクチュエータ装置、システム、および方法
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CA3144697A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6112009B2 (ja) 2012-02-29 2017-04-12 東レ株式会社 体腔液貯留抑制剤
PE20150226A1 (es) 2012-04-16 2015-02-14 Cantab Biopharmaceuticals Patent Ltd Agentes terapeuticos para administracion subcutanea optimizados
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2017189988A1 (en) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
PL3606946T3 (pl) 2017-04-03 2022-11-28 F. Hoffmann-La Roche Ag Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3086842A1 (en) * 2017-12-27 2019-07-04 Kyowa Kirin Co., Ltd. Il-2 variant
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
CA3125320A1 (en) 2019-01-28 2020-08-06 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
BR112021012472A2 (pt) 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN114051500A (zh) 2019-07-02 2022-02-15 豪夫迈·罗氏有限公司 包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021256936A1 (en) 2020-04-15 2022-07-21 F. Hoffmann-La Roche Ag Immunoconjugates
CN115551540A (zh) 2020-05-11 2022-12-30 豪夫迈·罗氏有限公司 使用经修饰的pbmc和免疫缀合物的组合疗法
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CN116635403A (zh) 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
CA3234731A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS54157816A (en) * 1978-05-27 1979-12-13 Unitika Ltd Fixing of bioactive substance to solid surface
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof

Also Published As

Publication number Publication date
JP2524586B2 (ja) 1996-08-14
KR900004801B1 (ko) 1990-07-06
FI93424B (fi) 1994-12-30
IE59406B1 (en) 1994-02-23
ZA864766B (en) 1988-02-24
IN163200B (da) 1988-08-20
GR861641B (en) 1986-09-12
DK97987D0 (da) 1987-02-25
IL79235A0 (en) 1986-09-30
JPS62503171A (ja) 1987-12-17
FI93424C (fi) 1995-04-10
FI870809A0 (fi) 1987-02-25
CA1291708C (en) 1991-11-05
PH25004A (en) 1991-01-28
WO1987000056A1 (en) 1987-01-15
NZ216618A (en) 1989-05-29
KR870000423A (ko) 1987-02-18
EP0229108A1 (en) 1987-07-22
EP0229108B1 (en) 1990-12-27
MX174442B (es) 1994-05-17
DK169874B1 (da) 1995-03-20
DE3676670D1 (de) 1991-02-07
IL79235A (en) 1991-01-31
PT82834B (pt) 1988-12-15
PT82834A (en) 1986-07-01
IE861706L (en) 1986-12-26
FI870809A (fi) 1987-02-25

Similar Documents

Publication Publication Date Title
DK97987A (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
DE3774274D1 (de) Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.
FI911319A0 (fi) Polypeptidderivat.
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
NO872227D0 (no) Tumor-nekrosefaktor-formulering.
DK276488A (da) Rekombinant pseudomonas exotoxin og opbygning af aktivt immunotoxin
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
FI874706A0 (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
ATE327254T1 (de) Interferon-beta fusionsproteine und deren verwendungen
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
DE3766157D1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
DK480284D0 (da) Sporstofmaerkede konjugater af metallothionein og maalsoegende, biologisk aktive molekyler
NO901986L (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
DE69008513D1 (de) Pharmazeutische formulierung von plasminogenaktivatorproteinen.
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
DK0918543T3 (da) Polymerpræparater til oral indgivelse af peptider og proteiner
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
RU96113877A (ru) Конъюгаты биологически активных веществ (бав) с альфа-фетопротеином (афп), обладающие избирательным действием по отношению к раковым опухолям, способ их получения (варианты) и фармацевтическая композиция на их основе
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired